TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/03/2026
Voltar para busca
Dado oficial do USPTO
TEVA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
57
Atualização mais recente
11/03/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
28/02/2017
Data de registro
15/12/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
15/12/2020
Última transação
11/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
21/09/2020
Primeiro uso no comércio
21/09/2020
Código do desenho
3
Tipo de titular
99
Localização do titular
Jerusalem, IL
Examinador
MICHELI, ANGELA M
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a line design that begins at the bottom center and rises up to the center right side. In the bottom right hand corner is the word TEVA with the letter v formed by 2 leaf shapes.
Titulares e representantes
Titulares
Teva Pharmaceutical Industries Limited
Representantes
Lori Wolfe Teva Pharmaceuticals USA, Inc.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system
Publicações
Histórico de despachos e eventos da marca no USPTO.
57 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/03/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/03/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/03/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/03/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
15/12/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
15/12/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/11/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/11/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
05/11/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/11/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
05/11/2020
SNEA
SU-EXAMINER'S AMENDMENT WRITTEN
05/11/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
30/10/2020
IUAF
USE AMENDMENT FILED
20/10/2020
EISU
TEAS STATEMENT OF USE RECEIVED
20/10/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
22/08/2020
EX5G
SOU EXTENSION 5 GRANTED
21/08/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
18/08/2020
EXT5
SOU EXTENSION 5 FILED
13/08/2020
EEXT
SOU TEAS EXTENSION RECEIVED
13/08/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
29/02/2020
EX4G
SOU EXTENSION 4 GRANTED
19/02/2020
EXT4
SOU EXTENSION 4 FILED
19/02/2020
EEXT
SOU TEAS EXTENSION RECEIVED
19/02/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
19/02/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
15/08/2019
EX3G
SOU EXTENSION 3 GRANTED
13/08/2019
EXT3
SOU EXTENSION 3 FILED
13/08/2019
EEXT
SOU TEAS EXTENSION RECEIVED
13/08/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
15/02/2019
EX2G
SOU EXTENSION 2 GRANTED
13/02/2019
EXT2
SOU EXTENSION 2 FILED
13/02/2019
EEXT
SOU TEAS EXTENSION RECEIVED
13/02/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
15/08/2018
EX1G
SOU EXTENSION 1 GRANTED
13/08/2018
EXT1
SOU EXTENSION 1 FILED
13/08/2018
EEXT
SOU TEAS EXTENSION RECEIVED
13/08/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
20/02/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/12/2017
PUBO
PUBLISHED FOR OPPOSITION
26/12/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/12/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/11/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
17/11/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
17/11/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
17/11/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
17/11/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/11/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/11/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/11/2017
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
26/05/2017
GPRA
PRIORITY ACTION E-MAILED
26/05/2017
CPRA
PRIORITY ACTION WRITTEN
26/05/2017
DOCK
ASSIGNED TO EXAMINER
23/05/2017
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
08/03/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/03/2017
NWAP
NEW APPLICATION ENTERED
03/03/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TEVA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.